Search research articles
Contact Us
Filters
Showing results (121-130 of 134) with videos related to
Page
of 14
Sort By:
Acta Neurologica Scandinavica
|
July 24, 2018
Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response
Marzia A L Romeo, Vittorio Martinelli, Gloria Dalla Costa, et al.
Frontiers in Neurology
|
June 21, 2018
Clinical Features of Headache in Patients With Diagnosis of Definite Vestibular Migraine: The VM-Phenotypes Projects
Roberto Teggi, Bruno Colombo, Roberto Albera, et al.
Frontiers in Neurology
|
February 11, 2020
Corrigendum: Clinical Features of Headache in Patients With Diagnosis of Definite Vestibular Migraine: The VM-Phenotypes Projects
Roberto Teggi, Bruno Colombo, Roberto Albera, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology
|
April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
International Journal of Environmental Research and Public Health
|
September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy
|
March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Neurology and Therapy
|
August 6, 2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Pain and Therapy
|
September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 134) with videos related to
Sort By:
Page
of 14
Acta Neurologica Scandinavica
|
July 24, 2018
Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response
Marzia A L Romeo, Vittorio Martinelli, Gloria Dalla Costa, et al.
Frontiers in Neurology
|
June 21, 2018
Clinical Features of Headache in Patients With Diagnosis of Definite Vestibular Migraine: The VM-Phenotypes Projects
Roberto Teggi, Bruno Colombo, Roberto Albera, et al.
Frontiers in Neurology
|
February 11, 2020
Corrigendum: Clinical Features of Headache in Patients With Diagnosis of Definite Vestibular Migraine: The VM-Phenotypes Projects
Roberto Teggi, Bruno Colombo, Roberto Albera, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology
|
April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
International Journal of Environmental Research and Public Health
|
September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy
|
March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Neurology and Therapy
|
August 6, 2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Pain and Therapy
|
September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Page
of 14